The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer.

Autor: Lee, Jangsoon1,2,3 (AUTHOR) jlee@cc.hawaii.edu, Kida, Kumiko1,4 (AUTHOR), Koh, Jiwon5,6 (AUTHOR), Liu, Huey1 (AUTHOR), Manyam, Ganiraju C.7 (AUTHOR), Gi, Young Jin1,2 (AUTHOR), Rampa, Dileep R.2 (AUTHOR), Multani, Asha S.8 (AUTHOR), Wang, Jing8 (AUTHOR), Jayachandran, Gitanjali9 (AUTHOR), Lee, Dae-Won5,10 (AUTHOR), Reuben, James M.9 (AUTHOR), Sahin, Aysegul11 (AUTHOR), Huo, Lei11 (AUTHOR), Tripathy, Debu1 (AUTHOR), Im, Seock-Ah5,10 (AUTHOR) moisa@snu.ac.kr, Ueno, Naoto T.1,2 (AUTHOR) nueno@cc.hawaii.edu
Zdroj: Journal of Experimental & Clinical Cancer Research (17569966). 8/20/2024, Vol. 43 Issue 1, p1-20. 20p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje